Azacitidine Maintenance After Allogeneic Hematopoietic Cell Transplantation for MDS and AML

Overview

Journal Blood Adv

Specialty Hematology

Date 2021 Mar 23

PMID 33755090

Citations 5

Authors

Firas El Chaer

Uma Borate

Remy Dulery

Shernan G Holtan

Arjun Datt Law

Lori Muffly

Samah Nassereddine

Rory M Shallis

Kate Stringaris

Justin Taylor

Steven M Devine

Mohamad Mohty

Christopher S Hourigan

Affiliations

Soon will be listed here.

Citing Articles

Measurable residual disease in patients undergoing allogeneic transplant for acute myeloid leukemia.

Wong Z, Dillon L, Hourigan C Best Pract Res Clin Haematol. 2023; 36(2):101468.

PMID: 37353292 PMC: 10291441. DOI: 10.1016/j.beha.2023.101468.

New drugs before, during, and after hematopoietic stem cell transplantation for patients with acute myeloid leukemia.

Mohty R, El Hamed R, Brissot E, Bazarbachi A, Mohty M Haematologica. 2023; 108(2):321-341.

PMID: 36722403 PMC: 9890036. DOI: 10.3324/haematol.2022.280798.

Current Status and Perspectives of Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia.

Sophie S, Yves B, Frederic B Stem Cells Transl Med. 2022; 11(5):461-477.

PMID: 35438781 PMC: 9154332. DOI: 10.1093/stcltm/szac015.

Prevention and Treatment of Acute Myeloid Leukemia Relapse after Hematopoietic Stem Cell Transplantation: The State of the Art and Future Perspectives.

Leotta S, Condorelli A, Sciortino R, Milone G, Bellofiore C, Garibaldi B J Clin Med. 2022; 11(1).

PMID: 35011994 PMC: 8745746. DOI: 10.3390/jcm11010253.

Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation-A Systematic Review and Meta-Analysis.

Bewersdorf J, Allen C, Mirza A, Grimshaw A, Giri S, Podoltsev N Transplant Cell Ther. 2021; 27(12):997.e1-997.e11.

PMID: 34551341 PMC: 9533376. DOI: 10.1016/j.jtct.2021.09.005.

References

Buckley S, Wood B, Othus M, Hourigan C, Ustun C, Linden M . Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. Haematologica. 2017; 102(5):865-873. PMC: 5477605. DOI: 10.3324/haematol.2016.159343. View

Platzbecker U, Wermke M, Radke J, Oelschlaegel U, Seltmann F, Kiani A . Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia. 2011; 26(3):381-9. PMC: 3306138. DOI: 10.1038/leu.2011.234. View

de Lima M, Giralt S, Thall P, de Padua Silva L, Jones R, Komanduri K . Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer. 2010; 116(23):5420-31. PMC: 5669059. DOI: 10.1002/cncr.25500. View

Ali N, Tomlinson B, Metheny L, Goldstein S, Fu P, Cao S . Conditioning regimen intensity and low-dose azacitidine maintenance after allogeneic hematopoietic cell transplantation for acute myeloid leukemia. Leuk Lymphoma. 2020; 61(12):2839-2849. DOI: 10.1080/10428194.2020.1789630. View

Short N, Zhou S, Fu C, Berry D, Walter R, Freeman S . Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis. JAMA Oncol. 2020; 6(12):1890-1899. PMC: 7545346. DOI: 10.1001/jamaoncol.2020.4600. View

Platzbecker U, Middeke J, Sockel K, Herbst R, Wolf D, Baldus C . Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. Lancet Oncol. 2018; 19(12):1668-1679. DOI: 10.1016/S1470-2045(18)30580-1. View

DeZern A, Elmariah H, Zahurak M, Rosner G, Gladstone D, Ali S . Shortened-Duration Immunosuppressive Therapy after Nonmyeloablative, Related HLA-Haploidentical or Unrelated Peripheral Blood Grafts and Post-Transplantation Cyclophosphamide. Biol Blood Marrow Transplant. 2020; 26(11):2075-2081. DOI: 10.1016/j.bbmt.2020.07.037. View

Oran B, de Lima M, Garcia-Manero G, Thall P, Lin R, Popat U . A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients. Blood Adv. 2020; 4(21):5580-5588. PMC: 7656915. DOI: 10.1182/bloodadvances.2020002544. View

Hourigan C, Dillon L, Gui G, Logan B, Fei M, Ghannam J . Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease. J Clin Oncol. 2019; 38(12):1273-1283. PMC: 7164487. DOI: 10.1200/JCO.19.03011. View

10.

Maples K, Sabo R, McCarty J, Toor A, Hawks K . Maintenance azacitidine after myeloablative allogeneic hematopoietic cell transplantation for myeloid malignancies. Leuk Lymphoma. 2018; 59(12):2836-2841. DOI: 10.1080/10428194.2018.1443334. View

11.

Schuurhuis G, Heuser M, Freeman S, Bene M, Buccisano F, Cloos J . Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018; 131(12):1275-1291. PMC: 5865231. DOI: 10.1182/blood-2017-09-801498. View

12.

de Lima M, Oran B, Champlin R, Papadopoulos E, Giralt S, Scott B . CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes. Biol Blood Marrow Transplant. 2018; 24(10):2017-2024. PMC: 8059405. DOI: 10.1016/j.bbmt.2018.06.016. View

13.

Hourigan C, McCarthy P, de Lima M . Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013; 20(2):154-63. PMC: 4205045. DOI: 10.1016/j.bbmt.2013.11.017. View

14.

Gilleece M, Labopin M, Yakoub-Agha I, Volin L, Socie G, Ljungman P . Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working.... Am J Hematol. 2018; 93(9):1142-1152. DOI: 10.1002/ajh.25211. View

15.

Xuan L, Wang Y, Huang F, Fan Z, Xu Y, Sun J . Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. Lancet Oncol. 2020; 21(9):1201-1212. DOI: 10.1016/S1470-2045(20)30455-1. View

16.

Burchert A, Bug G, Fritz L, Finke J, Stelljes M, Rollig C . Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With -Internal Tandem Duplication Mutation (SORMAIN). J Clin Oncol. 2020; 38(26):2993-3002. DOI: 10.1200/JCO.19.03345. View

17.

Guillaume T, Malard F, Magro L, Labopin M, Tabrizi R, Borel C . Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant. 2019; 54(11):1815-1826. DOI: 10.1038/s41409-019-0536-y. View

18.

Maziarz R, Levis M, Patnaik M, Scott B, Mohan S, Deol A . Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia. Bone Marrow Transplant. 2020; 56(5):1180-1189. PMC: 8113057. DOI: 10.1038/s41409-020-01153-1. View

19.

Craddock C, Jilani N, Siddique S, Yap C, Khan J, Nagra S . Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial. Biol Blood Marrow Transplant. 2015; 22(2):385-390. PMC: 4728172. DOI: 10.1016/j.bbmt.2015.09.004. View

20.

Mohty M . Maintenance after allogeneic HSCT in acute myeloid leukaemia. Lancet Oncol. 2020; 21(9):1130-1132. DOI: 10.1016/S1470-2045(20)30434-4. View